Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Completed
This is a Phase I, open label, dose escalation study of oral administration of MLN0128 in combination with paclitaxel, with/without trastuzumab, in participants with advanced solid malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2019
Locations: Not set, Fort Myers, Florida +2 locations
Conditions: Advanced Solid Malignancies, Hematologic Malignancies
Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Completed
A phase I study to evaluate safety of gemcitabine with nab-paclitaxel and concurrent IMRT for locally advanced and borderline resectable pancreatic cancer. The goal of this study is to evaluate if a chemotherapy regimen that provides superior systemic efficacy may be safely delivered and enhance efficacy of tumor directed radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2019
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Pancreatic Cancer
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Terminated
The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with treatment-naïve Stage 4 or recurrent non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2019
Locations: Pacific Cancer Medical Center, Inc, Anaheim, California +1 locations
Conditions: Lung Cancer
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Withdrawn
The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer. Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be gi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2019
Locations: UC San Diego Moores Cancer Center, La Jolla, California
Conditions: Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Completed
The purpose of this study is to find out the good and bad effects that occur when temsirolimus is added to standard chemotherapy with carboplatin and paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2019
Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey +4 locations
Conditions: Squamous Cell Cancer, Head and Neck Cancer
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Withdrawn
The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer. Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be gi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2019
Locations: Piedmont Cancer Institute, Atlanta, Georgia +2 locations
Conditions: Metastatic Pancreatic Cancer
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Completed
The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast Cancer (mBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2019
Locations: UC Davis Cancer Center, Sacramento, California +14 locations
Conditions: Breast Neoplasms, Pancreatic Neoplasms
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Withdrawn
This study will investigate the combination of two drugs, trametinib and nab-paclitaxel, in patients with advanced unresectable or metastatic melanoma. Each drug has shown activity in trials of patients with melanoma. However, the combination of these two drugs has not been studied. In this trial the investigators will determine the maximum dose of the drug combination to be administered to patients with advanced unresectable or metastatic melanoma and examine the safety profile of the drug comb... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: Colorado Blood Cancer Institute, Denver, Colorado +2 locations
Conditions: Melanoma
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Withdrawn
The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer. Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be gi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: HonorHealth Research Institute, Scottsdale, Arizona +5 locations
Conditions: Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether receiving combined carboplatin and paclitaxel plus continued low-dose paclitaxel is more effective than carboplatin and paclitaxel alone for early-stage ovarian cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel alone too see how well they work compared to c... Read More
Gender:
FEMALE
Ages:
120 years and below
Trial Updated:
05/23/2019
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +150 locations
Conditions: Ovarian Cancer
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Completed
The primary objective of this study is to determine the efficacy of nab-paclitaxel plus cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma (PDA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2019
Locations: Scottsdale Health Care, Scottsdale, Arizona +2 locations
Conditions: Stage IV Pancreatic Cancer
Study of SOR007 Ointment for Actinic Keratosis
Completed
A Phase 2, randomized, double-blind, dose rising study to determine the safety, tolerability, and preliminary efficacy of four concentrations of SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment (SOR007) compared to SOR007 ointment vehicle applied to actinic keratosis (AK) lesions on the face twice daily for up to 28 days.
Gender:
ALL
Ages:
Between 45 years and 85 years
Trial Updated:
05/02/2019
Locations: Moore Clinical Research, Tampa, Florida
Conditions: Actinic Keratosis